Eribulin as first- or second-line chemotherapy for advanced or metastatic HER2-negative breast cancer: A real-world prospective study

Authors :: Masato Takahashi
Kenichi Inoue
Junji Tsurutani
Chiyomi Egawa
Takashi Yamanaka
Yukinori Sakata
Hiroki Ikezawa
Toshiyuki Matsuoka
Hirofumi Mukai
Source :: Annals of Oncology. 29:viii100
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
business.industry
HER2 negative
Hematology
030204 cardiovascular system & hematology
medicine.disease
Second line chemotherapy
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Breast cancer
chemistry
Internal medicine
medicine
030212 general & internal medicine
business
Prospective cohort study
Eribulin

Full Text Access

Tools